24 March 2017 - Mood Disorders Society of Canada today released a groundbreaking brief recommending action to improve Canadians' access to the medications they need and to strengthen patients' role in the approval of new life-saving medications.

As the brief makes clear, successful treatment of a debilitating illness such as depression — now the leading cause of disability worldwide — can hinge on patients being able to access the right medication. But as Mood Disorder Society of Canada's research for the brief determined, Canadians suffering depression are too often prevented from obtaining the medications that would restore their full functionality and quality of life. 

People on limited incomes without private health plans, for example, cannot access medications unless they are publicly funded and the right one for them may not fall in that category.

Read Mood Disorders Society of Canada press release